Literature DB >> 3779500

The effects of cimetidine and ranitidine with and without metoclopramide on gastric volume and pH in morbidly obese patients.

A M Lam, D M Grace, P H Manninen, C Diamond.   

Abstract

The efficacy of preanaesthetic intravenous cimetidine versus ranitidine with and without metoclopramide for acid aspiration prophylaxis was assessed in 60 morbidly obese patients in a double-blind manner. Group 1 patients received cimetidine 300 mg + saline. Group 2 patients received cimetidine 300 mg + metoclopramide 10 mg. Group 3 patients received ranitidine 100 mg + saline. Group 4 patients received ranitidine 100 mg + metoclopramide 10 mg. Gastric fluid was aspirated for analysis of volume and pH following induction of anaesthesia. All four premedication regimens were equally effective in reducing the gastric volume and acidity and the inclusion of metoclopramide had no additive effect. Although statistically not significant, two patients in the cimetidine groups remained at risk (volume greater than 25 ml and pH less than 2.5) while no patients in the ranitidine groups remained so.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3779500     DOI: 10.1007/bf03027129

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


  30 in total

1.  Volume and pH of gastric juice in obese patients.

Authors:  R W Vaughan; S Bauer; L Wise
Journal:  Anesthesiology       Date:  1975-12       Impact factor: 7.892

2.  Prophylactic intravenous cimetidine reduces the risk of acid aspiration in morbidly obese patients.

Authors:  A M Lam; D M Grace; F J Penny; W C Vezina
Journal:  Anesthesiology       Date:  1986-12       Impact factor: 7.892

Review 3.  Ranitidine: a new H2-receptor antagonist.

Authors:  J B Zeldis; L S Friedman; K J Isselbacher
Journal:  N Engl J Med       Date:  1983-12-01       Impact factor: 91.245

4.  Delayed clearance of diazepam due to cimetidine.

Authors:  U Klotz; I Reimann
Journal:  N Engl J Med       Date:  1980-05-01       Impact factor: 91.245

5.  Cimetidine premedication in elective caesarean section.

Authors:  B G Pickering; R J Palahniuk; M Cumming
Journal:  Can Anaesth Soc J       Date:  1980-01

6.  Aspiration syndromes in pregnancy.

Authors:  S E Cohen
Journal:  Anesthesiology       Date:  1979-11       Impact factor: 7.892

7.  Effects of atropine, glycopyrrolate, and cimetidine on gastric secretions in morbidly obese patients.

Authors:  S L Wilson; N R Mantena; J D Halverson
Journal:  Anesth Analg       Date:  1981-01       Impact factor: 5.108

8.  Metoclopramide and cimetidine to reduce gastric fluid pH and volume.

Authors:  T L Rao; S Madhavareddy; M Chinthagada; A A El-Etr
Journal:  Anesth Analg       Date:  1984-11       Impact factor: 5.108

9.  Comparison of cimetidine (Tagamet) with antacid for safety and effectiveness in reducing gastric acidity before elective cesarean section.

Authors:  R Hodgkinson; R Glassenberg; T H Joyce; D W Coombs; G W Ostheimer; C P Gibbs
Journal:  Anesthesiology       Date:  1983-08       Impact factor: 7.892

10.  Gastric emptying before and after transverse gastroplasty for morbid obesity.

Authors:  W C Vezina; D M Grace; M J Chamberlain; R D Mowbray; M E Clare; R J Vanderwerf; M E King; S G Carruthers
Journal:  Clin Nucl Med       Date:  1986-05       Impact factor: 7.794

View more
  3 in total

1.  Gastric fluid volume and pH in elective inpatients. Part II: Coffee or orange juice with ranitidine.

Authors:  J R Maltby; C R Reid; A Hutchinson
Journal:  Can J Anaesth       Date:  1988-01       Impact factor: 5.063

2.  Gastric fluid volume and pH in elective surgical patients: triple prophylaxis is not superior to ranitidine alone.

Authors:  J R Maltby; R H Elliott; I Warnell; M Fairbrass; L R Sutherland; E A Shaffer
Journal:  Can J Anaesth       Date:  1990-09       Impact factor: 5.063

Review 3.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.